Paris-based kyron.bio, a seed-stage biotechnology company specializing in precision glycosylation of antibody therapeutics, and Servier, the privately held international pharmaceutical group also headquartered in France, have entered a strategic partnership under which kyron.bio will apply its proprietary glycoengineering platform to an antibody selected by Servier. Servier will fund the associated research activities and retains an option to further explore antibody engineering and development opportunities based on outcomes. The specific antibody, its molecular target, and the intended disease indication were not disclosed. Financial terms were not publicized.
Under the agreement, kyron.bio will seek to demonstrate precise glycan control on the Servier antibody for a specific, pre-determined N-glycoform. The deal is structured as a funded technology evaluation with an option for expanded collaboration rather than a full co-development or co-commercialization arrangement. No upfront payment, milestone schedule, royalty rates, territorial rights, or equity components were disclosed. The option-based structure suggests a staged approach, with Servier retaining the right to deepen the partnership contingent on proof-of-concept results.
Deal Context
kyron.bio's glycobiology platform addresses a technical challenge in biologics development: achieving comprehensive, scalable control over the glycan structures attached to antibodies. Glycosylation — the addition of sugar molecules to proteins — can affect antibody effector functions including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. By engineering defined glycan profiles, therapeutic antibodies can potentially be optimized for improved immune engagement and pharmacokinetics. The company uses proprietary cell-based systems and structure-guided design to modify N-glycan structures, a process it describes as precision glycosylation. kyron.bio was founded in 2022 to commercialize technology developed by CEO Emilia McLaughlin as part of the French Entrepreneur First Program. In 2025, the company raised EUR 5.5 million in a seed round from investors including HCVC, Verve Ventures, Entrepreneurs First, Saras Capital, and the European Innovation Council.
The kyron.bio Servier partnership originated from kyron.bio winning Servier's 2024 Golden Ticket award through the Spartners by Servier & BioLabs accelerator at Servier's Paris-Saclay R&D Institute. That program provided one year of hosting, access to Servier's laboratories, and mentorship. There were no prior commercial arrangements between the two companies before this partnership. For Servier, which generates approximately EUR 4.7 billion in annual revenue and reinvests 25% into R&D across oncology, cardiovascular, immuno-inflammatory, neuroscience, and diabetes, the deal represents a low-risk evaluation of a platform technology for next-generation antibody therapeutics without disclosed financial commitment beyond research funding.